Know Cancer

forgot password

A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma

18 Years
Open (Enrolling)
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma

Thank you

Trial Information

A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma


I. To evaluate the clinical benefit rate (complete response [CR], partial response [PR] or
standard disease [SD] >= 6 months) with BKM120 (PI3K inhibitor BKM120) in patients with
relapsed or refractory lymphoma.


I. To evaluate overall response rate, overall survival, progression-free survival and
duration of response.

II. To describe the toxicities associated with BKM120 in lymphoma. III. To evaluate
prognostic factors for aggressive lymphoma and whether there's a correlation with clinical


I. To assess serum cytokines before and after BKM120 therapy. II. To assess
phosphatidylinositol 3-kinase (PI3K) pathway member expression on paraffin-embedded tumor
samples pre-treatment.

III. To assess on paired fresh tumor tissue obtained from consenting patients pre- and
post-therapy the change in activation of PI3K pathway members.

OUTLINE: Patients receive PI3K inhibitor BKM120 orally (PO) on days 1-28. Courses repeat
every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 1 year.

Inclusion Criteria:

- Biopsy-proven relapsed, refractory or residual aggressive B-cell non-Hodgkin

- NOTE: re-biopsy is necessary unless the patient has had a previous biopsy < 168
days prior to registration on this protocol and there has been no intervening
treatment; eligible tumor types are diffuse large B-cell non-Hodgkin lymphoma
(NHL), mantle cell lymphoma, transformed NHL, and follicular grade III

- Not a candidate or has declined standard salvage therapy for their disease

- Measurable disease as defined by at least ONE of the following:

- Measurable disease by computed tomography (CT) or magnetic resonance imaging
(MRI) or the CT portion of the positron emission tomography (PET)/CT:

- Must have at least one lesion that has a single diameter of >= 2 cm or
tumor cells in the blood >= 5 x 10^9/L

- Skin lesions can be used if the area is >= 2cm in at least one diameter and
photographed with a ruler

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1, or 2

- Absolute neutrophil count (ANC) >= 1000/uL

- Hemoglobin (Hgb) >= 9 g/dl

- Platelet count (PLT) >= 100,000/uL

- Serum bilirubin within normal range (or =< 1.5 x upper limit of normal [ULN] if liver
metastases are present; or total bilirubin =< 3.0 x ULN with direct bilirubin within
normal range in patients with well documented Gilbert Syndrome)

- Aspartate aminotransferase (AST) within normal limits or =< 3 x ULN if due to

- Serum creatinine =< 1.5 x ULN or 24-hour clearance >= 50 mL/min

- Magnesium >= lower limit of normal (LLN)

- Potassium >= LLN

- Serum amylase =< ULN

- Serum lipase =< ULN

- Fasting plasma glucose =< 120 mg/dL (6.7 mmol/L)

- Serum calcium =< 10.9 mg/dL

- Negative pregnancy test done =< 72 hours prior to starting drug, for women of
childbearing potential only

- Provide informed written consent

- Willing to return to Mayo Clinic Rochester for follow-up

- Willing to provide blood samples for correlative research purposes

- Willingness to take BKM120 orally

Exclusion Criteria:

- Any of the following because this study involves an investigational agent whose
genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are

- Pregnant women

- Nursing women

- Women of childbearing potential who are unwilling to employ highly effective
contraception during dosing with BKM120 and for 4 weeks after the final dose of
treatment; NOTE: women of childbearing potential are defined as all women
physiologically capable of becoming pregnant

- Men of childbearing potential who are unwilling to employ highly effective
contraception during dosing with BKM120 and for 16 weeks after the final dose of
treatment and should not a father a child during this time; NOTE: men of
childbearing potential are defined as all males physiologically capable of
conceiving offspring

- NOTE: the highly effective contraception is defined as either:

- True abstinence: when this is in line with the preferred and usual
lifestyle of the subject; periodic abstinence (e.g., calendar,
ovulation, symptothermal, post-ovulation methods) and withdrawal are
not acceptable methods of contraception

- Sterilization: have had surgical bilateral oophorectomy (with or
without hysterectomy) or tubal ligation at least six weeks ago; in
case of oophorectomy alone, only when the reproductive status of the
woman has been confirmed by follow up hormone level assessment

- Male partner sterilization (with the appropriate post-vasectomy
documentation of the absence of sperm in the ejaculate); for female
subjects on the study, the vasectomized male partner should be the
sole partner for that patient

- Use of a combination of any two of the following (a+b):

1. Placement of an intrauterine device (IUD) or intrauterine system

2. Barrier methods of contraception: condom or occlusive cap
(diaphragm or cervical/vault caps) with spermicidal
foam/gel/film/cream/vaginal suppository

- Oral contraception, injected or implanted hormonal methods are not
allowed as BKM120 potentially decreases the effectiveness of hormonal

- Uncontrolled infection

- Average baseline of >= 4 stools per day

- Therapy with myelosuppressive chemotherapy or biologic therapy < 21 days prior to
registration unless the patient has recovered from the nadir of the previous
treatment to a level that meets the inclusion eligibility criteria of this protocol

- Patients who have received any continuous or intermittent small molecule therapeutics
(excluding monoclonal antibodies) =< 5 effective half-lives prior to registration or
who have not recovered from side effects of such therapy

- Received wide field radiotherapy =< 28 days or limited field radiation for palliation
=< 14 days prior to registration or who have not recovered from side effects of such

- Receiving corticosteroids > 10 mg of prednisone per day (or equivalent);

- NOTE: patients may be receiving stable doses of corticosteroids with a maximum
dose of 10 mg of prednisone per day if they are being given for disorders other
than lymphoma such as rheumatoid arthritis, polymyalgia rheumatica or adrenal
insufficiency, or asthma

- Persistent toxicities >= grade 2 from prior chemotherapy or biological therapy
regardless of interval since last treatment

- Active cardiac disease including any of the following:

- Left ventricular ejection fraction (LVEF) < 45% as determined by Multiple Grated
acquisition (MUGA) scan or echocardiogram (ECHO)

- Fridericia's corrected QT (QTcF) > 450 msec on screening electrocardiogram (ECG)
(using the QTcF formula)

- Unstable angina pectoris; patients with unstable angina should have angina
controlled before entering the study

- Ventricular arrhythmias except for benign premature ventricular contractions

- Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled
with medication

- Conduction abnormality requiring a pacemaker

- Symptomatic pericarditis

- Myocardial infraction within the last 6 months, documented by persistent
elevated cardiac enzymes or persistent regional wall abnormalities on assessment
of LVEF function

- History of documented congestive heart failure (New York Heart Association
functional classification III-IV)

- Documented cardiomyopathy

- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
considered investigational (utilized for a non-U.S. Food and Drug Agency
[FDA]-approved indication and in the context of a research investigation)

- Known positivity for human immunodeficiency virus (HIV);

- Note: baseline testing for HIV is not required

- Active hepatitis B or C with uncontrolled disease;

- Note: a detailed assessment of Hepatitis B/C medical history and risk factors
must be done at screening for all patients; hepatitis B surface antigen (HBsAg)
and hepatitis C virus (HCV) ribonucleic acid (RNA) polymerase chain reaction
(PCR) testing are required at screening for all patients with a positive medical
history based on risk factors and/or confirmation of prior hepatitis B virus
(HBV) infection

- Other active malignancy requiring treatment that would interfere with the assessments
of response of the lymphoma to protocol treatment

- Inability to swallow or impairment of gastrointestinal function or gastrointestinal
disease that may significantly alter the absorption of the drugs (e.g., ulcerative
disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small
bowel resection) that would preclude use of oral medications

- Any severe and/or uncontrolled medical conditions such as diabetes, poor lung
function, or other conditions that, in the treating physician's opinion, could
adversely impact their ability to participate in the study

- Patients who have received prior treatment with a P13K inhibitor; patients with prior
mammalian target of rapamycin (mTOR) inhibitor therapy are eligible

- Using medications that have a strong risk of prolonging the QT interval or inducing
torsades de pointes

- Major surgery =< 14 days prior to registration or have not recovered from side
effects of such therapy

- Currently being treated with drugs known to be moderate and strong inhibitors or
inducers of isoenzyme cytochrome P450 (CYP)3A4/5, (please note that co-treatment with
weak inhibitors of CYP3A is allowed)

- Receiving certain fruits or herbal preparations/medications including, but are not
limited to: St. John's wort, Kava, ephedra (ma huang), gingko biloba,
dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, ginseng; fruits include the
CYP3A inhibitors Seville oranges, grapefruit, pummelos, or exotic citrus fruits;

- NOTE: patients should stop using these fruits and herbal medications 7 days
prior to first dose of study drug

- Primary central nervous system (CNS) lymphoma or active metastases to the CNS;

- NOTE: active is defined as requiring therapy such as surgery, radiation, or
chemotherapy =< 28 days of study registration or ongoing corticosteroid therapy
for CNS disease

- The following mood disorders as judged by the Investigator or a psychiatrist, or as a
result of patient's mood assessment questionnaire:

- Medically documented history of or active major depressive episode, bipolar
disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of
suicidal attempt or ideation, or homicidal ideation (immediate risk of doing
harm to others)

- >= Common Terminology Criteria of Adverse Events (CTCAE) grade 3 anxiety

- Meets the cut-off score of >= 12 in the Patient Health Questionnaire (PHQ)-9 or
a cut-off of >= 15 in the Generalized Anxiety Disorder (GAD)-7 mood scale,
respectively, or selects a positive response of â1, 2, or 3â to question
number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of
the total score of the PHQ-9)

- Treated with any hematopoietic colony-stimulating growth factors (e.g., granulocyte
colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor
[GM-CSF]) =< 2 weeks prior to study registration;

- NOTE: erythropoietin or darbepoetin therapy, if initiated at least 2 weeks prior
to study registration, may be continued

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Clinical benefit defined as a PR or CR as the objective status at any time or an objective status of SD for a duration of greater than 6 months from registration

Outcome Description:

The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Ninety-five percent binomial confidence intervals for the true success proportion will be calculated.

Outcome Time Frame:

From 6 months from registration up to 2 years

Safety Issue:


Principal Investigator

Thomas E. Witzig, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic


United States: Food and Drug Administration

Study ID:




Start Date:

December 2012

Completion Date:

Related Keywords:

  • Recurrent Adult Diffuse Large Cell Lymphoma
  • Recurrent Grade 3 Follicular Lymphoma
  • Recurrent Mantle Cell Lymphoma
  • Lymphoma
  • Lymphoma, Follicular
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Mantle-Cell



Mayo Clinic Rochester, Minnesota  55905